A, a leading global life sciences company, has recently achieved European IVDR Class C Certification for its GenetiSure Dx Postnatal Assay. The certification is a testament to the assay meeting the stringent standards set by the In Vitro Diagnostic Regulation (IVDR), ensuring its continued availability for clinical geneticists and other healthcare professionals across the European Union (EU).
The GenetiSure Dx Postnatal Assay is a trusted qualitative assay used in diagnosing genetic disorders after birth. This certification is particularly significant as it signifies Agilent’s commitment to providing high-quality and reliable diagnostic tools to healthcare professionals throughout the EU. The company’s adherence to rigorous IVDR requirements ensures accurate results, allowing for more effective patient A
Agilent Technologies has recently announced further advancements in its portfolio of innovative solutions. One such announcement is the release of the Agilent ProteoAnalyzer system, an automated parallel capillary electrophoresis system designed specifically for protein analysis. This new platform simplifies and streamlines the analysis of complex protein mixtures, a critical process in various sectors, including pharmaceuticals, biotechnology, food analysis, and academia.
The ProteoAnalyzer system offers enhanced efficiency and accuracy in protein analysis, revolutionizing analytical workflows. By providing researchers and scientists with a reliable tool for protein analysis, Agilent Technologies aims to empower advancements in drug discovery, disease research, and various other protein-related applications.
Agilent Technologies has also received notable recognition for its Agilent Resolve Handheld Raman Spectrometer. The device has been commended for its excellence as an emergency response tool following independent evaluations by both the UK’s National CBRN Centre and the US Department of Homeland Security.
In the United Kingdom, the Resolve instrument was awarded the National CBRN (Chemical, Biological, Radiological, and Nuclear) Centre Certificate of Merit for 2023. This accolade reinforces the reliability and effectiveness of the Agilent Resolve Raman Spectrometer in identifying hazardous materials and chemical, biological, radiological, and nuclear threats. These recognitions reflect Agilent’s commitment to developing cutting-edge technology that assists emergency responders in protecting public safety.
In conclusion, Agilent Technologies has demonstrated its dedication to excellence in the field of life sciences through obtaining European IVDR Class C Certification for its GenetiSure Dx Postnatal Assay. In addition to achieving this milestone, the company’s recent advancements in the ProteoAnalyzer system and the Resolve Raman Spectrometer have garnered significant recognition. These developments reinforce Agilent’s position as a leading innovator, providing state-of-the-art solutions to professionals in various industries.
Comments